Objectives

• Identify and categorise technologies offering prospects for efficiency gains outside incremental innovations (higher quality/higher costs)

• Clarify under which conditions decremental cost-effectiveness is acceptable for collective health gains

• Develop a tool-box for use at a local level for HTA projects to maximise those health gains

​

Methodology

• Systematic search of clinical trials registries and published literature to identify decrementally cost-effective programmes, as for example non-drug interventions or non-inferiority trials

• Conduct a systematic enquiry into the willingness of stakeholders (namely patients, professionals, decision makers, tax payers) to accept a decremental efficacy

• A toolbox and guidance for HTA agencies to go beyond cost-effective comparators in their assessments and recommendations

​

​​

Outputs​

• Deliverable D11.1: Systematic review of decrementally cost-effective interventions [PDF]
   

• Deliverable D11.2: Stakeholders’ perspective: a political economy report [PDF]
   

• Deliverable D11.3: A toolbox on candidate cost-effective technologies for HTA producers and users [PDF]
   

• Work Package Overall Results [Poster PDF]

​

Publications

• Budget impact analysis of triple therapy after failure of methotrexate for the treatment of rheumatoid arthritis in France – ISPOR Europe [weblink]
   

• Annual cost of patients undergoing a total knee replacement in France – ISPOR Europe [weblink]

Leads

Paris School of Economics Hospital Innovation Economics (Hospinnomics)

 

Assistance Publique-Hôpitaux de Paris

Unité de Recherche Clinique en Économie de la Santé d’Ile de France (URC Eco)

​

Research team

Lise Rochaix (PI)

Isabelle Durand-Zaleski (PI)

Jean-Claude K. Dupont

Meryl Darlington

Emelie Lindström 

Ivan Tzintzun 

Jonathan Sicsic

Lucie Sabin

Rafaele Scarica

Xyomara Chavez Pacheco

Faustine Emmanuel